Chiara Zanetta

1.2k total citations
33 papers, 893 citations indexed

About

Chiara Zanetta is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Neurology. According to data from OpenAlex, Chiara Zanetta has authored 33 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 12 papers in Molecular Biology and 12 papers in Neurology. Recurrent topics in Chiara Zanetta's work include Multiple Sclerosis Research Studies (14 papers), Neurogenetic and Muscular Disorders Research (8 papers) and Polyomavirus and related diseases (5 papers). Chiara Zanetta is often cited by papers focused on Multiple Sclerosis Research Studies (14 papers), Neurogenetic and Muscular Disorders Research (8 papers) and Polyomavirus and related diseases (5 papers). Chiara Zanetta collaborates with scholars based in Italy, United States and Switzerland. Chiara Zanetta's co-authors include Stefania Corti, Monica Nizzardo, Giacomo P. Comi, Nereo Bresolin, Chiara Simone, Mafalda Rizzuti, Agnese Ramirez, Irene Faravelli, Giulietta Riboldi and Francesca Magri and has published in prestigious journals such as Annals of Neurology, Human Molecular Genetics and Journal of Hepatology.

In The Last Decade

Chiara Zanetta

27 papers receiving 881 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chiara Zanetta Italy 17 555 239 199 140 139 33 893
Sandra Klein Germany 10 284 0.5× 276 1.2× 299 1.5× 71 0.5× 229 1.6× 14 764
Johan Aarum Sweden 11 436 0.8× 205 0.9× 143 0.7× 46 0.3× 122 0.9× 15 1.1k
Donatella De Feo Switzerland 13 282 0.5× 126 0.5× 97 0.5× 188 1.3× 106 0.8× 19 896
J Piepmeier United States 11 214 0.4× 315 1.3× 154 0.8× 438 3.1× 177 1.3× 19 1.1k
Makoto Araie Japan 24 286 0.5× 95 0.4× 78 0.4× 96 0.7× 80 0.6× 57 1.5k
Xiaomei Xu China 13 554 1.0× 100 0.4× 27 0.1× 107 0.8× 176 1.3× 31 1.1k
Mark A. Hellmann Israel 16 135 0.2× 103 0.4× 616 3.1× 355 2.5× 152 1.1× 44 961
Ryan Salinas United States 15 489 0.9× 176 0.7× 47 0.2× 25 0.2× 49 0.4× 17 870
Claudio Maderna Italy 10 687 1.2× 77 0.3× 101 0.5× 18 0.1× 56 0.4× 13 1.0k

Countries citing papers authored by Chiara Zanetta

Since Specialization
Citations

This map shows the geographic impact of Chiara Zanetta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiara Zanetta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiara Zanetta more than expected).

Fields of papers citing papers by Chiara Zanetta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chiara Zanetta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiara Zanetta. The network helps show where Chiara Zanetta may publish in the future.

Co-authorship network of co-authors of Chiara Zanetta

This figure shows the co-authorship network connecting the top 25 collaborators of Chiara Zanetta. A scholar is included among the top collaborators of Chiara Zanetta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiara Zanetta. Chiara Zanetta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Copetti, Massimiliano, Chiara Zanetta, Francesco Patti, et al.. (2025). The Italian Multiple Sclerosis Register Experience With Cladribine. Neurology Neuroimmunology & Neuroinflammation. 12(4). e200415–e200415.
2.
Margoni, Monica, Paolo Preziosa, Chiara Zanetta, et al.. (2025). MOGAD-related epilepsy: a systematic characterization of age-dependent clinical, fluid, imaging and neurophysiological features. Journal of Neurology. 272(8). 508–508. 1 indexed citations
3.
Nozzolillo, Agostino, et al.. (2025). Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study. Journal of Neurology. 272(7). 481–481. 2 indexed citations
4.
5.
6.
Giossi, Riccardo, Massimo Filippi, Chiara Zanetta, et al.. (2024). Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy. Journal of Neurology. 271(11). 7186–7205.
7.
Nozzolillo, Agostino, Angela Genchi, Chiara Zanetta, et al.. (2023). Ocrelizumab extended‐interval dosing in multiple sclerosis during SARS‐CoV‐2 pandemic: a real‐world experience. European Journal of Neurology. 30(9). 2859–2864. 22 indexed citations
8.
Zanetta, Chiara, Maria A. Rocca, Alessandro Meani, et al.. (2023). Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study. Journal of Neurology. 270(7). 3553–3564. 17 indexed citations
9.
Montini, Federico, Agostino Nozzolillo, Paola M. V. Rancoita, et al.. (2023). Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case–control study. Journal of Neurology. 270(4). 1835–1842. 4 indexed citations
10.
Filippi, Massimo, Giovanna Borriello, Francesco Patti, et al.. (2023). Perspectives on Neuromyelitis Optica Spectrum Disorders, the Narrative Medicine contribution to care. Neurological Sciences. 45(4). 1589–1597. 1 indexed citations
11.
Zanetta, Chiara, Massimo Filippi, & Lucia Moiola. (2021). Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports. Neurological Sciences. 42(S1). 9–13. 3 indexed citations
12.
Moiola, Lucia, Agostino Nozzolillo, Stefano Gelibter, et al.. (2020). Telemedicine in/outside the pandemic: A survey about satisfaction of this tool in a cohort of multiple sclerosis patients and their neurologists. Multiple Sclerosis Journal. 26. 435–435. 1 indexed citations
13.
Brugliera, Luigia, Alfio Spina, Paola Castellazzi, et al.. (2020). Rehabilitative of COVID-19 patients with acute lower extremity Ischemia and amputation. Journal of Rehabilitation Medicine. 52(9). 0–0. 14 indexed citations
14.
Puthenparampil, Marco, Silvia Miante, Lisa Federle, et al.. (2016). BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset. Journal of Neuroimmunology. 297. 63–67. 24 indexed citations
15.
Faravelli, Irene, Giulietta Riboldi, Monica Nizzardo, et al.. (2014). Stem cell transplantation for amyotrophic lateral sclerosis: therapeutic potential and perspectives on clinical translation. Cellular and Molecular Life Sciences. 71(17). 3257–3268. 27 indexed citations
16.
Rinchetti, Paola, Francesca Magri, Giulietta Riboldi, et al.. (2014). The wide spectrum of clinical phenotypes of spinal muscular atrophy with respiratory distress type 1: A systematic review. Journal of the Neurological Sciences. 346(1-2). 35–42. 25 indexed citations
17.
Nizzardo, Monica, Chiara Simone, Sabrina Salani, et al.. (2014). Effect of Combined Systemic and Local Morpholino Treatment on the Spinal Muscular Atrophy Δ7 Mouse Model Phenotype. Clinical Therapeutics. 36(3). 340–356.e5. 44 indexed citations
18.
Rizzuti, Mafalda, Monica Nizzardo, Chiara Zanetta, Agnese Ramirez, & Stefania Corti. (2014). Therapeutic applications of the cell-penetrating HIV-1 Tat peptide. Drug Discovery Today. 20(1). 76–85. 181 indexed citations
19.
Govoni, Alessandra, Francesca Magri, Simona Brajkovic, et al.. (2013). Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy. Cellular and Molecular Life Sciences. 70(23). 4585–4602. 50 indexed citations
20.
Zanetta, Chiara, Monica Nizzardo, Chiara Simone, et al.. (2013). Molecular Therapeutic Strategies for Spinal Muscular Atrophies: Current and Future Clinical Trials. Clinical Therapeutics. 36(1). 128–140. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandra Klein Breakdown of academic impact, for papers by Johan Aarum Breakdown of academic impact, for papers by Donatella De Feo Breakdown of academic impact, for papers by J Piepmeier Breakdown of academic impact, for papers by Makoto Araie Breakdown of academic impact, for papers by Xiaomei Xu Breakdown of academic impact, for papers by Mark A. Hellmann Breakdown of academic impact, for papers by Ryan Salinas Breakdown of academic impact, for papers by Claudio Maderna
Rankless by CCL
2026